Navigation Links
Bradmer to present at the 10th Annual BIO CEO & Investor Conference
Date:2/8/2008

TSX: BMR

TORONTO, Feb. 8 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Dr. Alan M. Ezrin, President and Chief Executive Officer of the Company, will participate as a presenter and panelist at the 10th Annual BIO CEO & Investor Conference. Dr. Ezrin will provide an update on the Company's preparations for the planned Phase III trial for Neuradiab, a treatment for newly diagnosed glioblastoma multiforme (GBM), the most common form of brain cancer. The conference is being held at the Waldorf Astoria Hotel in New York City and Bradmer's corporate presentation is scheduled on Tuesday, February 12th at 2:45 PM ET in the Bleekman Suite. Dr. Ezrin will also be a panelist at the Neuro-Oncology Workshop, Neuro-oncology: "Breaking Down the Barriers to New Neuro-Oncology Drugs" session on Monday, February 11th from 9:30 to 10:55 AM ET in the East Foyer.

For more information on the BIO CEO & Investor Conference, visit the conference website at http://ceo.bio.org.

About Bradmer Pharmaceuticals Inc. (http://www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, the receipt of all regulatory approvals required to conduct the proposed clinical trial of Neuradiab, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bradmer announces additions to Scientific Advisory Board
2. Bradmer Medical Isotope Supply For Phase III Trial Secure
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. Bradmer provides Phase III Neuradiab trial update and guidance
5. Bradmer announces management changes
6. Mark Wylie and Suzy Preston Hoover Bring The Biggest Loser Million Pound Tour, Presented by MSN, to Dadeland Mall
7. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
8. QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravos The Real Housewives of Orange County
9. Assurant President and Chief Executive Officer Robert B. Pollock to Present at Merrill Lynch Insurance Investor Conference on February 12
10. CorVel to Present at UBS Global Healthcare Services Conference
11. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, today announced ... to the cloud. Cirracore provides a secure VMware® vCloud Air based cloud ... Transformation Solutions (TSL Partners) provides a full range of services from planning, ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... On January ... family scheduled an appointment after they noticed their furnace not producing any heat. Shortly ... heat exchanger. The cracked heat exchanger was leaking dangerous levels of carbon monoxide into ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
(Date:2/9/2016)... ... February 09, 2016 , ... ZipHearing.com is ... to affordable hearing aids , increase industry transparency, and promote awareness of ... States. , “For the average consumer, the hearing aid industry is esoteric and ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... N.Y., Feb. 9, 2016  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... debridement, cosmetic surgery, laparoscopic surgery and other surgical ... quarter and the first half of fiscal year ... --> --> Highlights for ...
(Date:2/9/2016)... -- Insulet Corporation (NASDAQ: PODD ) (Insulet or the Company), ... its OmniPod ® Insulin Management System, today ... to Insulet,s Board of Directors. With his appointment, the Board ... independent. --> --> Mr. ... and a deep knowledge of accounting, financial reporting and internal ...
(Date:2/9/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... its fourth quarter and full year 2015 financial ... therapeutic genome editing," said Edward Lanphier, Sangamo,s president ... (ZFN) technology leads the therapeutic genome editing field ... to move our ground-breaking genome editing programs through ...
Breaking Medicine Technology: